Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 9/20 | 0.51 |
| ▸ | MMP1 | P03956 | 2/20 | 0.51 |
| ▸ | MMP2 | P08253 | 3/20 | 0.45 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.40 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.40 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6511120 | 0.88 | MMP3 (0.50) | MMP3MMP1MMP2NMUR2NMUR1 | |
| SCHEMBL6510374 | 0.87 | MMP3 (0.61) | MMP3MMP1MMP2NMUR2NMUR1 | |
| SCHEMBL6510714 | 0.81 | MMP3 (0.54) | MMP3MMP1MMP2NMUR2NMUR1 | |
| SCHEMBL6510720 | 0.81 | MMP3 (0.54) | MMP3MMP1MMP2NMUR2NMUR1 | |
| SCHEMBL5551701 | 0.80 | MMP3 (0.62) | MMP3MMP1MMP2NMUR2NMUR1 | |
| SCHEMBL14599788 | 0.80 | MMP3 (0.62) | MMP3MMP1MMP2NMUR2NMUR1 | |
| SCHEMBL6514048 | 0.79 | MMP3 (0.56) | MMP3MMP1MMP2NMUR2NMUR1 | |
| SCHEMBL5551709 | 0.78 | MMP3 (0.59) | MMP3MMP1MMP2NMUR2NMUR1 | |
| SCHEMBL5552164 | 0.77 | MMP3 (0.52) | MMP3MMP1MMP2NMUR2NMUR1 | |
| SCHEMBL6511394 | 0.77 | MMP3 (0.55) | MMP3MMP1MMP2NMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050106100-A1 | Compounds containing matrix metalloproteinase substrates and methods of their use | LANTHEUS MEDICAL IMAGING, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050106100-A1 | Compounds containing matrix metalloproteinase substrates and methods of their use | MMP1, MMP10, MMP8 | MMP3 7/4885MMP1 1/4885MMP2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.